Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19

Braz J Infect Dis. 2021 Mar-Apr;25(2):101549. doi: 10.1016/j.bjid.2021.101549. Epub 2021 Feb 19.

Abstract

Objectives: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events.

Method: Retrospective comparative study, based in a quaternary private hospital in Rio de Janeiro, Brazil, involving 193 adult patients hospitalized for mild and moderate COVID-19 related ARSD, analyzing treatment efficacy based on clinical and biochemical outcomes.

Results: The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was 59 (47-70) in the active group and 65 (47-77) in the control group (p < 0.05). Patients in the control group had greater extent of pulmonary involvement on baseline chest CT scans (p < 0.05). All other baseline variables (BMI, comorbidities, previous use of medications and biochemical assessments) were similar between groups. In the medication group, 25% (25 out of 101) were admitted to the ICU, compared to 21% (19 out of 92) in the control group (p > 0.05). No difference in mortality, duration of non-invasive oxygen use or duration of hospitalization was seen between groups. The therapeutic regimen was well tolerated, with only eight (7.9%) patients presenting gastrointestinal symptoms and eight (7.9%) patients withdrawn treatment due to QTc prolongation.

Conclusions: Patients treated with hydroxychloroquine combined with azithromycin and the control group had similar clinical outcomes. This therapeutic regimen was considered ineffective in hospitalized patients with mild to moderate COVID-19 related ARDS and was associated with few non-severe adverse events.

Keywords: Azithromycin; COVID-19; Hydroxychloroquine; Severe acute respiratory syndrome coronavirus 2.

MeSH terms

  • Adult
  • Azithromycin / adverse effects
  • Brazil
  • COVID-19 Drug Treatment*
  • Drug Therapy, Combination
  • Humans
  • Hydroxychloroquine* / adverse effects
  • Middle Aged
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Hydroxychloroquine
  • Azithromycin